BOLD-100

BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu[1].

Product Specifications

CAS Number

[197723-00-5]

Product Name Alternative

NKP-1339; IT-139; KP-1339

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bold-100.html

Concentration

10mM

Purity

95.20

Solubility

DMSO : ≥ 59 mg/mL

Smiles

[Cl-][Ru+3]([Cl-])([Cl-])([N]1=CC2=C(N1)C=CC=C2)([N]3=CC4=C(N3)C=CC=C4)[Cl-].[Na+]

Molecular Formula

C14H12Cl4N4NaRu

Molecular Weight

502.14

Precautions

H302, H315, H319, H335

References & Citations

[1]Robert Trondl, et al. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science. Chemical Science|[2]Heffeter P, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer. 2013 Oct;49 (15) :3366-75.